Figure 3. Kaplan-Meier plots showing brain metastasis-specific progression-free survival for local treatment, subdivided by subtype. All p-values were obtained by the log-rank test. (A) HR+HER2-, p=0.143. (B) HR+HER2+, p=0.515. (C) HR-HER2+, p=0.025. (D) Triple-negative, p=0.001.

HR=hormone receptor; HER2=human epidermal growth factor receptor 2; FBT=focal brain treatment; TNBC=triple-negative breast cancer.